NCT03366103 2023-10-17
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Terminated
Clinical Trials
6 trialsNCT03205046 2021-01-06
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
Acerta Pharma BV
Phase 1/2 Terminated
NCT03061708 2019-05-20
AZD2014
Samsung Medical Center
Phase 2 Terminated
NCT03082833 2019-05-20
Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy
Samsung Medical Center
Phase 2 Terminated
NCT03106155 2018-09-20
[SUKSES-D]
Samsung Medical Center
Phase 2 Terminated
NCT01793636 2014-06-24
ZEBRA
Queen Mary University of London
Phase 2 Terminated